A phase IV, multicenter, single-arm and open-label study to explore the impact on quality of life of omalizumab (Xolair®) in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine (H1) treatment - SUNRISE

开始日期2015-01-28

申办/合作机构

Novartis Pharma SAS

EUCTR2014-003666-25-FR / Not yet recruiting临床3期

A 52-week, single-arm study to evaluate psoriasis severity and its psychosocial impact using the Simplified Psoriasis Index at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered subcutaneously in patients suffering from moderate to severe psoriasis. - IPSI-PSO

开始日期2015-01-16

申办/合作机构

Novartis Pharma SAS

EUCTR2014-002872-95-FR / Not yet recruiting临床4期

A French open-label extension study of canakinumab in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who participated in the international phase III study CACZ885G2301E1 - CACZ885GFR01

开始日期2014-09-15

申办/合作机构

Novartis Pharma SAS

100 项与 Novartis Pharma SAS 相关的临床结果

登录后查看更多信息

0 项与 Novartis Pharma SAS 相关的专利（医药）

登录后查看更多信息

294

项与 Novartis Pharma SAS 相关的文献（医药）

2024-07-01·British Journal of Haematology

Success of donor‐derived CAR‐T cells after failure of autologous CD19 CAR‐T cells (tisagenlecleucel) in B‐cell acute lymphoblastic leukaemia

Letter

作者: Caye-Eude, Aurélie ; Bergaoui, Karim ; Arfeuille, Chloé ; Delaugerre, Constance ; David, Audrey ; Caillat-Zucman, Sophie ; Auvin, Stéphane ; Cuffel, Alexis ; Thouvenin, Sandrine ; Naudin, Jérôme ; Baruchel, André ; Mebarki, Miryam ; Merlat-Guitard, Anne-Isabelle ; Chaillou, Delphine ; Chaix-Baudier, Marie-Laure ; Tardy, Cléa ; Yakouben, Karima ; Dourthe, Marie Emilie ; Dalle, Jean-Hugues ; Lainey, Elodie ; De Jorna, Romain

Tisagenlecleucel (tisacel) is an autologous product of T-lymphocytes that has been transduced with an anti-CD19 CAR construct containing the 4-1BB costimulatory domain.A key feature associated with durable complete remission (CR) is the persistence of the CAR-T cells reflected by B-cell aplasia.We report a patient who experienced multiple B- ALL relapses after allogeneic hematopoietic stem cell transplantation (allo-HSCT), received two unsuccessful infusions of tisacel and eventually obtained a durable CR after donor-derived CAR-T cells (DD-CAR) that were manufactured on the same circuit as the com. tisacel.In this case, we had the unique opportunity to compare the efficacy of 'autologous' CAR-T cells and DD-CAR originating from the same allogenic donor that were manufactured in the same way.Indeed, two previous tisacel infusions with an adequate dose of CAR-pos. T cells failed to expand and control leukemia.First, differences in the distribution of T cells were observed in the starting material, with a higher frequency of naive/stem cell memory and central memory CD8 T cells among apheresed DD-lymphocytes compared to the autologous ones.Here, for the very first time, the same CAR construct and manufacturing process authorized for com. tisacel were used for DD-CAR.The same strategy should be amplified through a prospective study to allow a com. access of DD- CAR.

2024-06-01·Acta Ophthalmologica

Management of diabetic macular oedema in France from 2012 to 2018: The nationwide LANDSCAPE study

Article

作者: Massin, Pascale ; Nghiem-Buffet, Sylvia ; Creuzot Garcher, Catherine P ; Ponthieux, Anne ; Girmens, Jean-Francois ; Delcourt, Cecile ; Srour, Mayer ; Collin, Cedric ; Baudin, Florian ; Dot, Corinne

AbstractObjectiveTo describe the management of diabetic macular oedema (DME) patients from the entire French population between 2012 and 2018.MethodsIn this retrospective longitudinal study, we identified adults treated for DME from the French population using the exhaustive French National Health Information database (SNDS), and an algorithm based on diagnosis and procedure codes, and reimbursed treatments.ResultsBetween 2012 and 2018, we identified 53 584 treated DME patients, who were followed for up to 7 years from DME treatment initiation. Optical coherence tomography (OCT) became the predominant imaging tool to diagnose DME.Only 14% of patients consulted a diabetologist or endocrinologist in the 3 months prior to initiating DME treatment, whereas 84% consulted a general practitioner. The percentage of patients consulting an ophthalmologist declined over time, from 97% of patients in Year 1 (median of 9 consultations), to 46% in Year 7 (median of 7 consultations).The median DME treatment duration with an anti‐VEGF and/or dexamethasone implant treatment was 9 months; 54% of patients had a treatment duration less than 1 year. First‐line treatment was more common with ranibizumab (55% of patients) than with aflibercept (30%), or dexamethasone implant (15%). About 25% of patients who initiated anti‐VEGF treatment switched treatment at least once, while 30% of patients who initiated dexamethasone implant switched to anti‐VEGF treatment at least once.ConclusionsFrench DME patients seem well‐monitored by their ophthalmologist, but median DME treatment duration was just 9 months. These results emphasise the challenge to manage and treat patients with DME over the long term.

2024-01-10·Journal of Clinical Oncology

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Article

作者: Garon, Edward B ; Thomas, Michael ; Lu, Shun ; Spigel, David R ; De Marchi, Pedro ; Mountzios, Giannis ; Ardizzoni, Andrea ; Myers, Andrea ; Cho, Byoung Chul ; Orlov, Sergey ; Carbini, Mariana ; Yang, James Chih-Hsin ; Barlesi, Fabrice ; Turri, Sabine ; Yoshioka, Hiroshige ; Bossen, Claudia ; Goto, Yasushi ; Khanna, Sadhvi ; Paz-Ares, Luis

Adjuvant canakinumab did not increase disease-free survival in resected non–small-cell lung cancer.

100 项与 Novartis Pharma SAS 相关的药物交易

登录后查看更多信息

100 项与 Novartis Pharma SAS 相关的转化医学

登录后查看更多信息